Status and phase
Conditions
Treatments
About
This was a Phase 2, double-blind, randomized, placebo-controlled study of IONIS-AGT-LRx conducted in mild hypertensive participants.
Full description
Participants were randomized in a 2:1 ratio to receive a once-weekly subcutaneous treatment and an additional loading dose on Study Day 3 with either IONIS-AGT-LRx or placebo for 6 weeks.
All participants completed a 13-week Post-Treatment Period.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Exclusion Criteria
Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a participant unsuitable for inclusion
The use of the following at time of screening and during the course of the study:
Unwilling to discontinue antihypertensive mediations during Wash Out (WO) and Treatment Period of study
Participant has a history of secondary hypertension
Unstable/underlying cardiovascular disease defined as:
Primary purpose
Allocation
Interventional model
Masking
25 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal